Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.

VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.69, showing minimal daily movement with a slight 0.07% decline. The technical picture remains bearish with moving averages signaling caution, though oscillators are neutral. The fund provides international real estate diversification with 682 holdings across 30+ countries, featuring a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent analysis highlights its role as a cost-effective diversifier for U.S.-focused real estate portfolios.

VNQI offers exposure to recovering global real estate markets with transaction volumes expected to grow over 10% in 2026. The fund trades at attractive valuations (0.9x P/B, 11.9x P/E) but faces headwinds from international market volatility and currency risks. While providing yield advantages over domestic peers, its total returns have lagged, making it suitable for investors seeking international diversification and income rather than growth leadership.